Studybox Research CLIA Waiver Studies
Chlamydia and Gonorrhea Point-of-Care Molecular Test
Accuracy in the hands of untrained intended-use operators at waived sites.
Studybox
CLIA Waiver Studies
Point-of-care molecular tests for chlamydia and gonorrhea have been cleared and waived for vaginal swabs and male urine, and the study design that supported them is now well understood: a composite reference of two or more cleared laboratory NAATs defines patient infected status, performance is reported for each organism, each specimen type and each sex, and asymptomatic and symptomatic subjects are analyzed separately. Each of those strata needs its own positives.
Gonorrhea prevalence in women attending general clinics is low, which makes the female gonorrhea arm the long pole of almost every study. Sexual health clinics supply positives but are staffed by experienced clinicians; waived settings supply the right operators but fewer positives. The site plan typically blends both, and sample size planning should model prevalence by site type rather than assuming a single rate.
- Analyte
- Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid
- Therapeutic area
- STD/STI Detection
- Specimens
- Vaginal Swab, Urine
- Intended-use settings
- urgent care, physician office, pharmacy, emergency department
- Operators
- Non-laboratory clinic staff in waived settings running a sample-to-answer molecular instrument; laboratory staff for moderate-complexity claims.
- Comparator
- Typically a patient infected status (PIS) composite reference built from two or more FDA-cleared laboratory nucleic acid amplification tests, with specimen-type-specific rules for resolving disagreement.
CLIA Waiver Studies specifics
What Changes for This Assay on This Pathway.
- Waived-setting operators transfer the swab or urine into the cartridge; flex studies typically stress sample volume, transfer-pipette use, delays before cartridge insertion and instrument environment.
- Low gonorrhea prevalence at waived sites means the waiver study may need many more sites than a laboratory study would, or a pre-agreed plan for supplementing positives.
- Same-visit results change treatment behavior; the protocol should address whether site clinicians act on investigational results or wait for the laboratory comparator.
Endpoints the study must support
- Sensitivity and specificity for C. trachomatis and N. gonorrhoeae separately, by specimen type and by sex, against the composite reference, with 95% confidence intervals
- Performance in symptomatic and asymptomatic subjects separately
- Self-collected versus clinician-collected vaginal swab agreement where both are claimed
- Invalid and error rates by site in waived settings
Enrollment realities
Driven by N. gonorrhoeae positives in women, then by asymptomatic positives in each stratum; studies typically enroll thousands of subjects across many sites to fill the female gonorrhea cell, and each additional specimen type multiplies the enrollment.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Waiver evidence depends on genuine intended-use operators in genuine waived settings. Our network of 100+ pre-qualified urgent care, physician office, and point-of-care sites already runs IVD protocols, so operator recruitment and site activation don't start from zero. How we run clia waiver studies →
Same assay, other pathways
Relevant FDA guidance
- Recommendations for Dual 510(k) and CLIA Waiver by Application Studies
- Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices
- Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program
- Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
FAQ
Chlamydia and Gonorrhea Point-of-Care Molecular Test Study Questions.
01 Who operates the chlamydia and gonorrhea point-of-care molecular test in a clia waiver studies study?
Non-laboratory clinic staff in waived settings running a sample-to-answer molecular instrument; laboratory staff for moderate-complexity claims.
02 What is the comparator for a chlamydia and gonorrhea point-of-care molecular test study?
Typically a patient infected status (PIS) composite reference built from two or more FDA-cleared laboratory nucleic acid amplification tests, with specimen-type-specific rules for resolving disagreement.
03 What drives enrollment for a chlamydia and gonorrhea point-of-care molecular test study?
Driven by N. gonorrhoeae positives in women, then by asymptomatic positives in each stratum; studies typically enroll thousands of subjects across many sites to fill the female gonorrhea cell, and each additional specimen type multiplies the enrollment.
Let's talk IVD research
Planning a chlamydia and gonorrhea point-of-care molecular test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the clia waiver studies pathway.